341 Studies Now Enrolling
Menu
Search
Medical Condition
- Show all (1595)
- Addiction (14)
- Allergy, Asthma, & Immunology (12)
- All of Us Research Program - NIH (1)
- Autoimmune Disorders (26)
- Blood Disorders (37)
- Bone & Muscle (8)
- (-)
Cancer
(655)
- Bladder Cancer (12)
- Brain Cancer (16)
- Breast Cancer (67)
- Gastrointestinal (14)
- Gynecologic Cancer (25)
- Head and Neck Cancer (4)
- Kidney Cancer (7)
- Leukemia (71)
- Liver Cancer (9)
- Lung Cancer (60)
- Lymphoma (36)
- Multiple Myeloma (25)
- Pancreatic Cancer (15)
- Prostate Cancer (31)
- Sarcoma (25)
- Skin Cancer (30)
- Solid Tumors (42)
- Thyroid Cancer (1)
- Uveal Melanoma (7)
- Child Development (4)
- COVID-19 (Coronavirus) (28)
- Critical Illness (1)
- Dental (2)
- Diabetes (15)
- Ear, Nose and Throat (5)
- Endocrine & Metabolic Disease (11)
- Eye (7)
- Gastrointestinal and Digestive Diseases (20)
- Hair and Skin Disorders (1)
- Headaches (5)
- Healthy Volunteers (135)
- Heart Disease (105)
- Infectious Disease (35)
- Insomnia (2)
- Kidney Disease (12)
- Liver Disease (34)
- Lung Disease (29)
- Meniere's Disease (1)
- Neurological Disorders (134)
- Nutrition (5)
- Obesity (2)
- Obstetrics & Gynecology (40)
- Pain Management (1)
- Pediatrics (80)
- Psychiatric Disorders (58)
- Rehabilitation (7)
- Stroke (6)
- Surgery (7)
- Transplant (37)
- Urology (4)
- Vascular Conditions (9)
Displaying 201 - 400 of 655
Condition: Cancer
Investigator: Benjamin Herzberg, MD
Status: Closed
The purpose of this study is to compare two treatment programs for smoking cessation. Providing treatment medication at no cost to participants and providing additional counseling sessions could help more participants quit smoking and stay smoke-free. However, it could also cause side effects. There will be about 308 people taking part in this study.
Condition: Cancer
Investigator: Ryan Moy, MD
Status: Closed
The purpose of this study is to find out if two drugs, MEDI9253 and durvalumab, will be safe for the treatment of solid tumors. MEDI9253 and durvalumab are types of cancer therapies that try to boost the immune system to fight cancer. MEDI9253 is an oncolytic virus (a virus that infects and breaks down cancer cells but not normal cells) and may also help…
Condition: Cancer / Lung Cancer
Investigator: Catherine Shu, MD
Status: Closed
This study is aimed at finding patients who have small amounts of cancer DNA in their blood (called circulating tumor DNA or ctDNA) after surgery. This may indicate that you have minimal residual disease (MRD), meaning that even after surgery, there are still some remaining cancer cells releasing cancer DNA into your bloodstream. MRD after surgery may mean…
Condition: Cancer
Investigator: Jennifer Amengual, MD
Status: Closed
This study is designed to test different doses of FLX475 to see if it is safe and to study how the drug is absorbed and how the human body gets rid of the drug. The study will test FLX475 alone and in combination with pembrolizumab, a drug already approved by the United States Food and Drug Administration (FDA) for the treatment of patients with certain…
Condition: Skin Cancer / Melanoma
Investigator: Mariam El-Ashmawy, MD, PhD
Status: Closed
This study consists of two treatment groups, Part 1 and Part 2. The purpose of this study is to: Part 1 - Test the safety and tolerability of the study drug IN10018, see how well the drug works on your metastatic uveal melanoma, and see how your body handles the drug. Part 2 - Test the safety and tolerability of the study drug IN10018 with cobimetinib, see…
Condition: Cancer / Lung Cancer
Investigator: Catherine Shu, MD
Status: Closed
The purpose of this research study is to find out if a drug called capmatinib is safe and effective (can help people) in people who have non-small cell lung cancer (NSCLC) who are also eligible for surgery. Capmatinib is an oral drug that targets particular processes, which may not be working properly in the cancer cells (dysregulation) in the body. Prior…
Condition: Cancer / Lung Cancer
Investigator: Catherine Shu, MD
Status: Closed
The purpose of this study is to see if lazertinib and JNJ-61186372 are safe and useful for treating patients with a type of lung cancer called advanced non-small cell lung cancer (NSCLC) as well as looking at the effects that lazertinib and JNJ-61186372 have when taken together. Lazertinib is taken orally and JNJ-61186372 is an intravenous drug. Lazertinib…
Condition: Cancer / Sarcoma
Investigator: Mark Stein, MD
Status: Closed
The purpose of this study is to: 1. Compare treatment with chemotherapy (paclitaxel) alone to using a combination of nivolumab plus chemotherapy (paclitaxel) treatment in patients with angiosarcoma who have not been treated with paclitaxel chemotherapy alone. 2. Evaluate the effect of nivolumab in combination with cabozantinib on angiosarcoma (cancer) in…
Condition: Cancer
Investigator: Shaheer Khan, DO
Status: Closed
The purpose of this study is to see if the investigational drug MPT-0118 is effective in treating people with cancer. This is the first time the study drug, MPT-0118, will be given to humans. MPT-0118 will be given alone (monotherapy) and in combination with Keytruda (pembrolizumab). Pembrolizumab is approved by the FDA to treat certain types of cancer. MPT…
Condition: Cancer
Investigator: Dawn Hershman, MD
Status: Closed
In this study, we are evaluating a 30-minute pharmacist-led video consultation to provide education about your new oral anti-cancer drug (OACD) and help identify and manage potential drug-drug interactions alongside your oncologist. Our study aims to evaluate a one-time, 30-minute pharmacist-led video visit among patients starting OACDs. During the video…
Condition: Cancer
Investigator: Brian Henick, MD
Status: Closed
To evaluate the proportion of patients with objective response (OR) to targeted study agent(s) in patients with advanced refractory cancers/lymphomas (including breast cancer, esophageal cancer, lung cancer, sarcomas - bone and soft tissue), thyroid cancer, cervical cancer, ovarian cancer, Hodgkin's disease, non-Hodgkin's lymphoma, pancreatic…
Condition: Cancer
Investigator: Ryan Moy, MD
Status: Closed
This is a Phase I/IIa study, which means that there is some but limited clinical experience in SHR-A1904 (the study drug) clinical trials conducted outside the USA. In this study, the sponsor (Jiangsu Hengrui Pharmaceuticals Co., Ltd.) and study doctors want to learn: How much of the study drug can be given with an acceptable level of side effects. About…
Condition: Cancer / Solid Tumors
Investigator: Mark Stein, MD
Status: Closed
The purpose of this study is to test what dose of BPX-601 can be given safely with rimiducid to patients with certain types of cancer. The study will look for side effects (good and bad) and how your body responds to the treatment. The study will also see if the treatment helps to stop your cancer from growing or spreading. BPX-601 is a treatment made from…
Condition: Cancer / Lymphoma
Investigator: Barbara Pro, MD
Status: Closed
The main purpose of this research study is to determine if the study drug CPO107 can be used safely in participants who have been diagnosed with non-Hodgkins lymphoma (NHL) and have failed at least two prior conventional anti-cancer drugs. Other purposes of the study are to monitor how the study drug is distributed and broken down inside the body. All…
Condition: Cancer
Investigator: Gulam Manji, MD, PhD
Status: Closed
The purpose of this study is to determine the effectiveness of combining immune therapy with standard chemotherapy. People who usually have this are treated with 3 cycles of standard chemotherapy, followed by surgery, and then another 3 cycles of chemotherapy. In this study, all study subjects will receive the standard of care chemotherapy for 3 cycles…
Condition: Cancer / Multiple Myeloma
Investigator: Suzanne Lentzsch, MD
Status: Closed
You are being asked to take part in this study because you have Multiple Myeloma. This study is being done to learn more about AMG 701 in people with Multiple Myeloma. It will see if AMG 701 is safe and tolerable and whether it causes any side effects. This study will also look at what doses of AMG 701 are safe for people to take and what the effect on…
Condition: Cancer / Sarcoma
Investigator: Gary Schwartz, MD
Status: Closed
The purpose of this study is to test the study drug, BI 907828 for safety, effectiveness, and side effects when compared to receiving the standard treatment, doxorubicin, in subjects with dedifferentiated liposarcoma (DDLPS). BI 907828 has proven to minimize a critical protein interaction between MDM2 and p53, two proteins in your body, which when their…
Condition: Cancer / Bladder Cancer
Investigator: Joel DeCastro, MD, MPH
Status: Closed
We are doing this research to find out the safety, toxicity, and efficacy of intravesical Cabazitaxel, Gemcitabine, and Cisplatin (CGC) in the treatment of non-muscle-invasive urothelial carcinoma of the bladder that has recurred despite BCG use. The purpose of finding the maximum tolerable dose is important for future use of the drug, so as to provide the…
Condition: Cancer / Leukemia
Investigator: Ran Reshef, MD
Status: Closed
Patients who will be receiving immune effector cell (IEC) therapy for the treatment of their cancer (leukemia) are being asked to participate in this study. IEC can produce a harmful side effect called Cytokine Release Syndrome (CRS). CRS involves a release of a large amount of proteins into the bloodstream. This may cause changes in blood pressure and…
Condition: Cancer / Breast Cancer
Investigator: Bret Taback, MD
Status: Closed
The purpose of this study is to compare usual lymph node surgery to an added procedure during the surgery to help surgeons see the lymph node system better. During usual surgery, the lymph node system may be disrupted, which can cause swelling in the arm. This research study will use a new lymph node surgery technique to look at how fluid drains through the…
Condition: Cancer / Prostate Cancer
Investigator: Mark Stein, MD
Status: Closed
The purpose of this study is to see if a new, experimental drug called JNJ-75229414 is safe and useful for treating patients with metastatic castration-resistant prostate cancer. JNJ-75229414 is a Chimeric Antigen Receptor T Cell (CAR-T) cell therapy. This is the first time that JNJ75229414 will be used in humans. In this type of treatment, your white blood…
Condition: Cancer / Breast Cancer
Investigator: Bret Taback, MD
Status: Closed
The purpose of this study is to examine whether removing some of the lymph nodes from the armpit, but not removing them all followed with radiation therapy (experimental) will be as good as having the majority of the lymph nodes from the armpit removed during breast surgery followed with radiation(standard of care). Patients will be randomized to either of…
Condition: Cancer
Investigator: Bret Taback, MD
Status: Closed
Surgery is the main treatment for many cancer conditions. In many elderly patients, surgery can greatly affect physical condition, and the ability to return to pre-surgery levels of physical functioning. By providing some simple pre-surgical recommendations, it may be possible to improve the rate of recovery from surgery and the possibility that patients…
Condition: Cancer / Leukemia
Investigator: Joseph Jurcic, MD
Status: Closed
The purpose of this study is to compare the effects, both good and bad, of magrolimab in combination with azacitidine, to those of azacitidine in combination with placebo, to find out which is better for treating patients with MDS (Myelodysplastic Syndrome). Other purposes of this study include determining the quantity of magrolimab in the blood, aspects of…
Condition: Cancer
Investigator: Richard Carvajal, MD
Status: Closed
The purpose of this study is to assess the safety and tolerability of an experimental study drug called ulixertinib (BVD-523) in the treatment of advanced cancer that shows certain genetic alterations (changes in the DNA) called MEK or atypical BRAF alterations and is getting worse. Experimental means that ulixertinib has not received authorization to be…
Condition: Cancer / Breast Cancer
Investigator: Julia McGuinness, MD
Status: Closed
The purpose of this study is to find out, good and/or bad, the effects of the investigational drug, Imprime PGG, when given together with pembrolizumab (also known as Keytruda, a type of checkpoint inhibitor) in the treatment of your type of cancer. Checkpoint inhibitors are a type of immunotherapy that block immune checkpoint proteins from binding with…
Condition: Cancer / Pancreatic Cancer
Investigator: Gulam Manji, MD, PhD
Status: Closed
The purpose of this study is to determine the feasibility of administering personalized therapy to subjects who have been newly diagnosed with pancreatic cancer and have not yet received treatment.
Condition: Cancer
Investigator: Nicole Lamanna, MD
Status: Closed
The purpose of this study is to compare the effects, good or bad, of the experimental drug BGB-3111, versus a known standard treatment called bendamustine plus rituximab (B+R) on you and your chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) to find out which is better. In this study, you will receive either BGB-3111 or the standard…
Condition: Cancer / Lymphoma
Investigator: Jennifer Amengual, MD
Status: Closed
This study is being done to answer the following question: If we add the study drug nivolumab to standard chemotherapy will it extend your time without disease more than or less than if we add the study drug brentuximab vedotin to standard chemotherapy? We will also compare any side effects you may have and your well-being when you take the study drugs and…
Condition: Cancer
Investigator: Richard Carvajal, MD
Status: Closed
The purpose of this clinical research study is to find out if an Investigational Drug, called LN-144/LN-145, is safe and beneficial in the treatment of participants with Metastatic Melanoma, or head and neck squamous cell carcinoma (HNSCC) when given in combination with a medication, named pembrolizumab (Keytruda), or in participants with non-small cell…
Condition: Cancer / Breast Cancer
Investigator: Meghna Trivedi, MD
Status: Closed
This is a first-in-human, phase 1/1b, open-label study of single-agent PMD-026 conducted in participants with metastatic breast cancer. PMD-026 will initially be administered orally on a once-daily schedule. Part 1 of the study will evaluate PMD-026 in participants with metastatic breast cancer that have not responded to treatment, which may involve…
Condition: Cancer
Investigator: Benjamin Izar, MD
Status: Closed
The purpose of this clinical trial is to find a safe and tolerated dose of the study treatment COM701 in combination with BMS-986207 and nivolumab for the treatment of advanced solid tumors. These drugs are being developed to fight cancer by using your immune system to fight the cancer cells (known as immunotherapies). These study drugs are also known as…
Condition: Cancer
Investigator: Matthew Ingham, MD
Status: Closed
The purpose of this research study is to study the safety and efficacy of GSK3901961 and GSK3845097 when used to treat synovial sarcoma or non-small cell lung cancer and to examine if your tumor affects how the study drug works. You will need to receive chemotherapy for 3 to 4 days (depending on your age and your medical condition) before you are given…
Condition: Cancer / Gastrointestinal
Investigator: Yoanna Pumpalova, MD
Status: Closed
This study evaluates whether the addition of immune therapy to usual FOLFOX chemotherapy in patients with deficient DNA mismatch repair stage III colon cancer can improve your outcome compared to FOLFOX alone. The immune therapy drug, atezolizumab, may allow your body's immune system to more effectively kill cancer cells in your body. One of the…
Condition: Cancer / Prostate Cancer
Investigator: Karie D. Runcie, MD
Status: Closed
The purpose of this study is to assess the effectiveness and safety of combining an investigational drug called BMS-986218 (also known as Anti-CTLA4-NF monoclonal antibody), or BMS-986218 plus nivolumab, with standard of care docetaxel (chemotherapy), in men who have metastatic castration-resistant prostate cancer (mCRPC) that progressed after a second-…
Condition: Cancer / Leukemia
Investigator: Andrew Lipsky, MD
Status: Closed
The purpose of this study is to assess the safety, effectiveness, pharmacokinetic (PK how long the drug is in your body and how it is metabolized) and pharmacodynamics (PD where does the drug go in your body and what is its biological effect) of the study drug, GFH009, in patients with relapsed or refractory hematologic malignancies including acute myeloid…
Condition: Cancer / Gastrointestinal
Investigator: Yoanna Pumpalova, MD
Status: Closed
The purpose of this study is to compare the effects, good or bad, of the cancer immunotherapy combination treatments (CIT) combinations versus standard treatment on you and your colorectal cancer to find out which is better.
Condition: Cancer / Pancreatic Cancer
Investigator: Susan Bates, MD
Status: Closed
The purpose of this study is to determine the effectiveness of combining immune therapy, pembrolizumab, with a hypomethylating agent, azacitidine, for pancreatic cancer. People who have advanced pancreatic cancer with disease progression on first-line therapy are usually treated with a second chemotherapy regimen. However, there is no single accepted…
Condition: Cancer
Investigator: Melissa Accordino, MD
Status: Closed
Many patients with metastatic cancer experience frustration with the large number and complex scheduling of their medications. This study will help us find out how much pill burden exists in patients with advanced cancer, and how a smartphone app can help patients take their medications as their providers prescribe. Results of this study may help us figure…
Safety, Tolerability, Efficacy and Pharmacokinetics of Copanlisib in Pediatric Patients (ages 18-21)
Condition: Cancer
Investigator: Luca Szalontay, MD
Status: Closed
The purpose of this study is to find out the effects and safety of an investigational (experimental) new drug called copanlisib in pediatric patients from 6 months to 21 years of age. This study consists in two-phase, Phase I part will determine which is the right dose of copanlisib to be used in children/adolescents/adults with relapsed (has returned) or…
Condition: Cancer
Investigator: Matthew Ingham, MD
Status: Closed
The purpose of this study is to: test the safety of the study drug and see how your body handles it, find the highest dose of the study drug that can be given alone or in combination with embrolizumab (MK-3475) with the least risk of serious side effects. The study drug is called MK-2118. Solid tumor or lymphoma cancers include: bladder cancer, breast…
Condition: Cancer / Multiple Myeloma
Investigator: Suzanne Lentzsch, MD
Status: Closed
This is a research study. We invite you to participate in this research study because you have been diagnosed with Multiple Myeloma (MM). Your previous treatment(s) has/have not been successful and your cancer is progressing. The purpose of this research study is to see if selinexor (also known as KPT-330) has any effects on your cancer. Selinexor is…
Condition: Cancer
Investigator: Gulam Manji, MD, PhD
Status: Closed
The purpose of this study is to determine how safe and effective the combination of atezolizumab, cobimetinib, and hydroxychloroquine is at treating KRAS-mutated advanced malignancies, and also to determine the maximum dose of this combination of drugs that can be tolerated by patients. This combination is thought to work by increasing the body's…
Condition: Cancer / Brain Cancer
Investigator: Andrew Lassman, MD
Status: Closed
The purpose of this research study is to see if the combination of medications approved for the treatment of glioblastoma, together with the study drug, selinexor (also known as XPOVIO), has any effects on your cancer. Selinexor works by trapping tumor suppressor proteins within the cell nucleus. This is expected to cause the cancer cells to die or stop…
Condition: Cancer / Prostate Cancer
Investigator: Mark Stein, MD
Status: Closed
The purpose of this study is to determine if the addition of immunotherapy to the current standard of care for metastatic prostate cancer, chemotherapy, and hormonal therapy, is safe and improves your response to therapy. People who usually have metastatic prostate cancer to their bones and organs are usually treated with combination of chemotherapy (…
Condition: Cancer
Investigator: Matthew Ingham, MD
Status: Closed
The purpose of this study is to test the safety and dose of CDK-002 alone in subjects with cancer that is considered advanced and/or has spread to other parts of the body. CDK-002 is an investigational study drug that is being developed for the potential treatment of cancer. This is a first-in-human study. CDK-002 is a drug designed to activate the immune…
Condition: Cancer / Prostate Cancer
Investigator: Karie D. Runcie, MD
Status: Closed
The purpose of this study is to see whether immunotherapy with BMS-986218 added to degarelix (which suppresses your testosterone) given prior to surgery can decrease the chance that your cancer will come back compared to degarelix alone. People who usually have this type of prostate cancer usually do not receive any additional therapy prior to surgery.
Condition: Cancer / Breast Cancer
Investigator: Melissa Accordino, MD
Status: Closed
The purpose of this study is to assess the safety and effectiveness of giving anastrozole, palbociclib, trastuzumab, and pertuzumab to women with hormone receptor-positive, HER2-positive metastatic breast cancer. This combination of medications represents an all-biologic approach and avoids chemotherapy as first-line treatment of this disease.
Condition: Cancer / Leukemia
Investigator: Joseph Jurcic, MD
Status: Closed
The purpose of this clinical research study is to evaluate the safety (any good or bad effects) of CYNK-001 and to assess the effects of CYNK-001 on your Acute Myeloid Leukemia (AML). Also, the study plans to determine the maximum tolerated dose (highest safe dose) of CYNK-001 and assess whether CYNK-001 can eliminate your residual (leftover) disease.…
A Study of PTC596 in Combination With Dacarbazine in Participants With Advanced Leiomyosarcoma (LMS)
Condition: Cancer / Sarcoma
Investigator: Matthew Ingham, MD
Status: Closed
The purpose of this study is to evaluate the effectiveness of a new investigational drug, PTC596, used in combination with dacarbazine, for the treatment of locally recurrent, unresectable, or metastatic relapsed/refractory leiomyosarcoma, a type of soft tissue sarcoma. The purpose of this study is to evaluate whether adding PTC596 to dacarbazine is safe…
Condition: Cancer
Investigator: Brian Henick, MD
Status: Closed
The purpose of this study is to explore how the combination of the study drugs affects tumors and general health. The study drugs are BMS-986253 and nivolumab. Participants will be given different doses of BMS-986253 and nivolumab to test how safe they are in humans. This is the first study in which BMS-986253 is being given in combination with nivolumab.
Condition: Cancer / Pancreatic Cancer
Investigator: Gulam Manji, MD, PhD
Status: Closed
The purpose of this study is to learn which treatment works best in patients with pancreatic cancer. The study explores multiple treatment combinations. A study drug called atezolizumab may be combined with other drugs such as cobimetinib, PEGPH20, and BL-8040. Patients may also be assigned to receive standard chemotherapy treatment.
Condition: Cancer / Solid Tumors
Investigator: Ryan Moy, MD
Status: Closed
The purpose of the study is to test the safety of the study drug, ASTX029, and to find the appropriate dose of this experimental drug to use in this and other studies. The drug that will be given to you in this study, ASTX029, is investigational. This means it has not been approved for treatment of any disease, including cancer.
Condition: Cancer
Investigator: Benjamin Izar, MD
Status: Closed
The main purposes of this research study are: to find a safe and tolerated dose of the study drug COM701 alone and in combination with nivolumab; and to measure the amount of COM701 that is in the blood at different times after it is given. This study is for people with advanced cancer (solid tumor) that no longer responds to standard approved therapies.
Condition: Cancer / Multiple Myeloma
Investigator: Ran Reshef, MD
Status: Closed
The purpose of this research study is to obtain information on the safety and effectiveness of PBCAR269A to treat certain types of cancers. PBCAR269A is a new investigational treatment for certain types of cancer of the blood, such as multiple myeloma. It is made from a type of blood cells known as T cells. The T cells in PBCAR269A came from people who have…
Condition: Cancer / Bladder Cancer
Investigator: Joel DeCastro, MD, MPH
Status: Closed
This is a Phase 1 study (the first time this treatment is being tested in humans) of an anti-cancer study drug called as PF-07225570. This study drug works on stimulating certain cells in the immune system. The study will test different doses that increase (dose escalation) and at the appropriate time, additional patients will be enrolled to evaluate this…
Condition: Cancer
Investigator: Brian Henick, MD
Status: Closed
The purpose of this study is to learn about the safety and anti-cancer effectiveness of the investigational study drug called PF-07263689, as a single agent and in combination with sasanlimab, another investigational study drug that is an anti-PD 1 antibody. PF 07263689 is a weakened, live virus form of the pox-type virus (related to smallpox) and has been…
Condition: Cancer
Investigator: Mark Stein, MD
Status: Closed
The purpose of this study is to learn about the study drug RTX-240. This study is the first time RTX-240 will be used in people. Researchers will be studying the safety and effectiveness of RTX-240 in patients with certain types of cancer. The study will check if RTX-240 causes any changes in your health (or side effects), how well it may work at treating…
Condition: Cancer
Investigator: Mark Stein, MD
Status: Closed
This study will test the investigational drug, DS-7300a, for the first time in humans. DS-7300a is an antibody-drug conjugate (ADC) being developed as an anti-cancer agent. ADCs are made up of a monoclonal antibody chemically linked to a drug. The monoclonal antibody binds to specific proteins or receptors found on certain types of cells, including cancer…
Condition: Cancer / Solid Tumors
Investigator: Richard Carvajal, MD
Status: Closed
The purpose of this study is to determine the highest dose of the study drug that can be given safely to people with certain cancers. The study will also look at how effective the study drug is in treating certain cancers. The study drug is PLX2853. The participants in this study will be the first people to receive PLX2853.
Condition: Cancer
Investigator: Matthew Ingham, MD
Status: Closed
The main purpose of this study is to determine the safety of administering an investigational new drug (referred to as INT230-6 or the study drug) directly into multiple superficial (you can feel them with touch) and deep tumors (such as those within the body or inside an organ e.g. the liver). Investigational means that INT230-6 has not yet been approved…
Condition: Cancer / Skin Cancer
Investigator: Richard Carvajal, MD
Status: Closed
The purpose of the study is to determine the long-term effectiveness and safety of cemiplimab in patients diagnosed with Cutaneous Squamous Cell Carcinoma (CSCC, a type of skin cancer).
Condition: Cancer / Prostate Cancer
Investigator: Mark Stein, MD
Status: Closed
In Phase 1b, the purpose is to learn how well patients with Metastatic Castration-Resistant Prostate Cancer (mCRPC) tolerate the treatment when PLX2853 is added to ongoing treatment with abiraterone acetate and prednisone. We are looking for the highest dose of PLX2853 that can be given safely to patients with your type of disease who are already on…
Condition: Cancer / Brain Cancer
Investigator: Andrew Lassman, MD
Status: Closed
This study is being done to evaluate the safety and usefulness of the study drug, AG-881, as compared to placebo (a medically inactive substance) in residual or recurrent non-enhancing Grade 2 glioma (a type of brain cancer) that has a mutation in the IDH1 or IDH2 metabolic enzyme (a substance produced by the body to assist in breaking down chemicals).…
Condition: Cancer / Solid Tumors
Investigator: Mark Stein, MD
Status: Closed
The purpose of the study is to test the safety of an investigational study drug called BMS-986249. BMS-986249 will be given alone and in combination with nivolumab. This study will investigate how patients with advanced solid tumors tolerate these drugs. The study will identify the highest dose or most suitable dose of BMS-986249 alone and in combination…
Condition: Cancer / Brain Cancer
Investigator: Andrew Lassman, MD
Status: Closed
The purpose of this research study is to test how safe and how well an investigational drug known as ONC201 works in treating high grade glioma (a type of brain cancer). The FDA (the U.S. Food and Drug Administration) has not approved ONC201 as a treatment for this condition.
Condition: Cancer / Breast Cancer
Investigator: Melissa Accordino, MD
Status: Closed
The purpose of this study is to determine whether there is clinical benefit to continue therapy beyondprogression for metastatic or unresectable breast cancer. The treatment that is being investigated in this clinical trial, ribociclib (LEE011), is part of a family of oral medications (pills) that are called Cyclin Dependent Kinase 4 and 6 inhibitors, which…
Condition: Cancer / Sarcoma
Investigator: Gary Schwartz, MD
Status: Closed
The purpose of this study is to find out if an investigational drug, called ADP-A2M4, is safe and how well it works in attacking Synovial Sarcoma or Myxoid/Round Cell Liposarcoma (MRCLS) cancer cells. The study involves taking certain types of immune cells from the blood, called T cells, and changing them in a laboratory before putting them back into the…
Condition: Cancer / Lung Cancer
Investigator: Catherine Shu, MD
Status: Closed
The purpose of this research study is to see how effective durvalumab andtremelimumab is in patients with early stage non-small cell lung cancer (NSCLC). A a special blood test will be done to see if subjects have circulating tumor DNA (ctDNA) in their blood. ctDNA are pieces of genetic material shed from the tumor cells that can be detected in the blood,…
Condition: Cancer / Breast Cancer
Investigator: Eileen Connolly, MD, PhD
Status: Closed
The purpose of the study is to determine whether ablation, which is the removal or destruction of a tumor (through SBRT and/or surgical resection of all known metastases) in oligometastatic breast cancer patients improves progression-free survival (PFS) and overall survival (OS).
Condition: Skin Cancer / Squamous Cell Carcinoma
Investigator: Richard Carvajal, MD
Status: Closed
The purpose of this study is to test the good and bad effects of the combined treatment, using the drugs cetuximab and avelumab as well as avelumab by itself. Avelumab is a drug that works by triggering the immune system so it can try to attack the cancer again. Avelumab works in a similar way to cemiplimab, which is the usual drug for treatment of your…
Condition: Cancer
Investigator: Markus Mapara, MD
Status: Closed
The purpose of this study is to find out what effects (good and bad) an investigational (not approved by the Food and Drug Administration) drug, RGI-2001 has on you and graft-versus-host disease (GVHD). GVHD is a side effect of blood or bone marrow stem cell transplant that sometimes can be deadly. This study is trying to see if the experimental drug, RGI-…
Condition: Cancer
Investigator: Richard Carvajal, MD
Status: Closed
The purpose of this research study is to find out if you can take part in one or more of the treatment studies sponsored by Immatics. The "treatment studies" involve adoptive cellular therapy (ACT), a type of therapy in which T cells (a type of immune cell) are given to a participant to help the body fight diseases, such as cancer. If your tumor…
Condition: Cancer
Investigator: Richard Carvajal, MD
Status: Closed
The purpose of this study is to learn about the study drug BDC-1001 in patients with HER2-expressing tumors. Researchers will be studying the use of BDC-1001 alone as well as in combination with Pembrolizaumab. This study will help researchers learn if the study drug can help with HER2-expressing tumors and how people respond to the drug. The researchers…
Condition: Cancer / Breast Cancer
Investigator: Diana Martinez, MD
Status: Closed
Paclitaxel is frequently used to treat breast cancer, but it can also cause neuropathy where the nerves of the hands and feet stop working properly. The symptoms of neuropathy can include pain, numbness, and difficulty with everyday activities like walking or typing. Paclitaxel-induced neuropathy is common and there are few treatment options. Our study will…
Condition: Cancer / Breast Cancer
Investigator: Katherine Crew, MD
Status: Closed
This research study involves receiving an experimental drug referred to as ZN-c5. This is the first study in humans using ZN-c5. The purpose of this research study is to test the safety of ZN-c5 at different dose levels. This study is designed to find out what effects, good and/or bad, ZN-c5 has on participants with breast cancer. Participants in both…
Condition: Cancer / Leukemia
Investigator: Nicole Lamanna, MD
Status: Closed
This research study is evaluating an investigational drug, called cirmtuzumab, in combination with astandard drug, called ibrutinib (Imbruvica), as a possible treatment for patients with CLL/SLL or MCL. All cells in the body receive signals to grow and survive, but sometimes these signals get out of control, causing too much cell growth. When the growth of…
Condition: Cancer / Solid Tumors
Investigator: Mark Stein, MD
Status: Closed
The primary purpose of this research study is to learn the safety and tolerability of the investigational drug, XmAb 22841 when given alone or in combination with another drug called pembrolizumab. You will be assigned to either receive XmAb22841 alone or in combination with pembrolizumab and you will know what treatment you are receiving. This study will…
Condition: Cancer
Investigator: Mark Stein, MD
Status: Closed
GEN-011 is an experimental treatment being evaluated in adult patients with advanced cancer. GEN-011 is a T cell therapy made specific to each patient, using the patient's own circulating immune cells. First, the cancer proteins that are already recognized by the patient's T cells are found. Then, immune cells that recognize these cancer proteins…
Condition: Cancer / Prostate Cancer
Investigator: Mark Stein, MD
Status: Closed
The purpose of this study is to test the effectiveness and safety of an experimental drug known as HPN424 (also known as study drug) in patients with advanced prostate cancer. This drug has been tested in animals but not yet in people. This study tests different doses of HPN424. We want to find out how good the drug is at treating prostate cancer. We also…
Condition: Skin Cancer / Melanoma
Investigator: Richard Carvajal, MD
Status: Closed
The purpose of the study is to evaluate the effectiveness (how well the drug works) of the investigational drug called bempegaldesleukin when combined with drug nivolumab in comparison with nivolumab alone after complete resection (removal of all sites of known disease) of melanoma in participants at high risk of cancer returning after surgery (recurrence).
Condition: Cancer / Solid Tumors
Investigator: June Hou, MD
Status: Closed
The experimental drug being investigated in this study is called rucaparib. Rucaparib is being developed by Clovis Oncology, Inc. (the Sponsor), a biopharmaceutical company with headquarters in the United States (US). Rucaparib (trade name: Rubraca) is a medicine that is approved in the European Union (EU) and the US for use in certain types of ovarian…
Condition: Cancer / Kidney Cancer
Investigator: Mark Stein, MD
Status: Closed
This research study is a phase II clinical trial. Phase II clinical trials test the safety and effectiveness of an investigational treatment to learn whether the intervention works in treating a specific disease. Investigational means that the intervention is being studied. The Food and Drug Administration (FDA) has approved Nivolumab as treatment for…
Condition: Cancer
Investigator: Andrew Lassman, MD
Status: Closed
The purpose of the study is to evaluate the tolerability of a ketogenic diet in conjunction with metformin in people with malignant glioma. The study doctors will try to determine if maintaining the ketogenic diet with metformin will have any effect on your tumor.
Condition: Cancer / Breast Cancer
Investigator: Melissa Accordino, MD
Status: Closed
The purpose of this study is to identify if blood sugar elevations during chemotherapy may be related to the development of side effects from chemotherapy. This study will help us find out if blood sugar goes up during the course of chemotherapy, and if so, for the amount of time the blood sugar is elevated after a chemotherapy treatment. Results of this…
Condition: Skin Cancer / Melanoma
Investigator: Mariam El-Ashmawy, MD, PhD
Status: Closed
This research study is a phase II clinical trial that will study the combination of adjuvant nivolumab and ipilimumab for the treatment of adult subjects with completely treated high-risk ocular melanoma. This study is being done to see if the combination of the study drugs is safe and effective in preventing the return of their cancer. If you are eligible…
Condition: Cancer / Brain Cancer
Investigator: Andrew Lassman, MD
Status: Closed
The purpose of this study is to measure how well and how safe eflornithine is in combination with lomustine, compared to lomustine taken alone, in treating patients whose anaplastic astrocytoma has come back after radiation and chemotherapy. Safety and how well you can tolerate the drug will be determined on the basis of physical exams, laboratory tests,…
Condition: Cancer
Investigator: Brian Henick, MD
Status: Closed
The purpose of this research study is to learn more about an experimental personalized vaccine that has two components called GRT-C901 and GRT-R902. We will learn more about the effects of this vaccine on your cancer when used together with approved medications that activate the immune system, nivolumab (Opdivo) as well as ipilimumab (Yervoy), which are…
Condition: Cancer / Solid Tumors
Investigator: Brian Henick, MD
Status: Closed
The main purpose of the study is to determine at what dose the study drug (ASP1951) is safe and tolerated and how it is processed in the blood of subjects with tumors that cannot be removed (unresectable) or has spread (metastasized) to a different part of the body. When the safe dose is identified, it will be used to evaluate if the study drug treatment…
Condition: Cancer / Breast Cancer
Investigator: Meghna Trivedi, MD
Status: Closed
The purpose of this study is to compare the usual approach (i.e. no more treatment or additional post-operative chemotherapy), to any effects, good and/or bad, of the experimental drug MK-3475 (also called pembrolizumab) after surgery. This study will allow the researchers to know whether treatment with MK-3475 (pembrolizumab) is better, the same, or worse…
Condition: Cancer
Investigator: Ran Reshef, MD
Status: Closed
The goal of the study is to learn if it is safe to give genetically changed T cells (IMA201) in combination with standard of care chemotherapy (fludarabine and cyclophosphamide) and IL-2 (aldesleukin) to patients with solid tumors that have grown or returned after being treated. Researchers also want to learn about possible side effects of IMA201 and if the…
Condition: Cancer
Investigator: Ran Reshef, MD
Status: Closed
The goal of the overall study is to learn if it is safe to give genetically changed T cells (IMA202) in combination with standard of care chemotherapy (fludarabine and cyclophosphamide) and IL-2 (aldesleukin) to patients with melanoma solid tumors that have grown or returned after being treated. Researchers also want to learn about possible side effects of…
Condition: Cancer / Gastrointestinal
Investigator: Rachael Safyan, MD
Status: Closed
This study is being done to answer the following question: Does duloxetine (either 30 mg or 60 mg) prevent numbness, tingling, and/or pain caused by your colorectal cancer treatment with oxaliplatin? We are doing this study because we want to find out if duloxetine can prevent Oxaliplatin-Induced Peripheral Neuropathy (OIPN).
Condition: Cancer
Investigator: Matthew Ingham, MD
Status: Closed
The purpose of this study is to test the safety and effectiveness of the study drug, BI 1387446, given alone or combined with the study drug, BI 754091, in subjects with different types of advanced cancer. BI 1387446 will be injected directly into at least one tumor site. BI 754091 will be given by intravenous (IV) infusion, which is a slow injection of the…
Condition: Cancer / Sarcoma
Investigator: Gary Schwartz, MD
Status: Closed
The purpose of this study is to test the safety of a study drug called AMG 232 given with radiation in patients with soft tissue sarcoma (STS) prior to surgery. The AMG 232 is investigational. It has been tested in other cancers but not yet in sarcoma. AMG 232 has not been tested using the dosing schedule in this study and it has not been tested with…
Condition: Cancer / Solid Tumors
Investigator: Ryan Moy, MD
Status: Closed
The purpose of this study is to evaluate OBT076, which is a drug that combines an antibody with an anti-cancer drug. This class of drugs are called Antibody-Drug Conjugates (ADC). Antibodies are normally produced in the human body by the immune system to fight infections but can be designed to target cancer cells and deliver an anti-cancer drug. OBT076 is…
Condition: Cancer / Sarcoma
Investigator: Gary Schwartz, MD
Status: Closed
You are being asked to participate in this study because you have been diagnosed with a progressive desmoid tumor. The purpose of this study is to see if the study drug, called AL102 (referred to from now on as the study drug), is safe and effective in people with progressive desmoid tumors. The study will also look at how your body responds to the study…
Condition: Cancer / Leukemia
Investigator: Mark Heaney, MD, PhD
Status: Closed
The purpose of this study is to find out what dose of pacritinib is safest and works best for participants. Pacritinib is an experimental drug, which is a drug that is being tested and is not currently approved by the Food and Drug Administration (FDA) in the US. The study will be conducted at about 85 study clinics in North America, Europe, Israel and…
Condition: Cancer
Investigator: Mark Stein, MD
Status: Closed
This research study will learn more about the drug, XmAb20717. XmAb20717 is designed to activate your own cells to kill your tumor. The primary purposes of this research study are to: determine the safety and tolerability of XmAb20717, see if XmAb20717 works in treating specific tumors , learn about the side effects from XmAb20717. Cancers include:…
Condition: Cancer / Solid Tumors
Investigator: Brian Henick, MD
Status: Closed
BioAtla (the sponsor of the clinical trial) is studying BA3021 as a potential treatment for varieties of cancers including but not limited to lung, triple negative breast cancer and soft tissue sarcoma. The purpose of this research study is to test the safety of different doses of BA3021 and to find out what effects, good and/or bad, it has on the body and…
Condition: Cancer / Liver Cancer
Investigator: Gulam Manji, MD, PhD
Status: Closed
The purpose of this study is to compare the effects, good or bad, of atezolizumab plus bevacizumab versus observation (not receiving any treatment) on patients with completely resected (surgically removed) or ablated (removed using heat) hepatocellular carcinoma (the most common type of liver cancer) who are at high risk for disease recurrence.…
Condition: Cancer
Investigator: Richard Carvajal, MD
Status: Closed
This primary purpose of this study is to find the recommended dose of LGK974 and PDR001 that can be safely given to adult patients who have advanced metastatic pancreatic cancer, or triple negative breast (TNB) cancer, or melanoma, lung squamous cell cancer, esophageal squamous cell cancer, cervical squamous cell cancer, or head and neck squamous cell…
Condition: Cancer / Prostate Cancer
Investigator: Mark Stein, MD
Status: Closed
This study is for patients with prostate cancer and that require treatment because their disease is now growing. The purpose of this study is to see whether immunotherapy with nivolumab added to degarelix or nivolumab and BMS-986253 added to degarelix is safe and can decrease the chance that the cancer will come back. Degarelix is a standard of care drug…
Condition: Cancer / Kidney Cancer
Investigator: Mark Stein, MD
Status: Closed
This study will test whether cabozantinib in combination with nivolumab plus ipilimumab is more effective (works better) than nivolumab plus ipilimumab alone in treating patients with advanced kidney cancer who have not received prior treatment for their cancer. This study will also examine how safe cabozantinib is in combination with nivolumab plus…
Condition: Cancer / Bladder Cancer
Investigator: Joel DeCastro, MD, MPH
Status: Closed
This research study will investigate an experimental, unapproved drug that will be given two different ways; as an injection in the bladder wall after bladder tumor resection surgery (or TURBT) and then as an intravesical instillation (fluid inserted in the bladder by catheter) right after the injection. The purpose of this study is to find the dose which…
Condition: Cancer / Leukemia
Investigator: Joseph Jurcic, MD
Status: Closed
The purpose of this study is to: Test if the lifespan of study participants is increased when uproleselan is added to standard chemotherapy medicines compared to standard chemotherapy alone; test if the number of study participants achieving disease remission is increased when uproleselan is added to standard chemotherapy medicines compared to standard…
Condition: Cancer
Investigator: Brian Henick, MD
Status: Closed
The purpose of this study is to test the good and bad effects of the drug called CB-839 HCl (telaglenastat). CB-839 HCl (telaglenastat) could shrink your cancer, but it could also cause side effects. The study doctors hope to learn if the study drug will help control the disease in patients with advanced cancer with changes in specific genes. We don't…
Condition: Cancer / Breast Cancer
Investigator: Meghna Trivedi, MD
Status: Closed
The purpose of this study is to compare any good and bad effects of using olaparib and atezolizumab in combination compared to olaparib alone. The use of olaparib alone or in combination with atezolizumab could shrink your cancer but could also cause side effects. This study will allow the researchers to know whether the combination approach is better, the…
Condition: Cancer
Investigator: Dawn Hershman, MD
Status: Closed
The purpose of this study is to see if using a digital device to track when and how often you take your pain medication and provide feedback to your doctor is a practical way for patients and physicians to communicate about pain. We also want to see if patients will continue to use the sensor patch for the length of the study which is 6 weeks.
Condition: Skin Cancer / Squamous Cell Carcinoma
Investigator: Sewanti Limaye, MD
Status: Closed
The purpose of this study is to determine the effectiveness and safety of study drug MEDI4736 monotherapy, tremelimumab monotherapy, and MEDI4736 and tremelimumab combination therapy in the treatment of patients with recurrent or metastatic PD-L1-negative squamous cell carcinoma of the head and neck who have progressed during or after treatment with…
Condition: Cancer
Investigator: Meghna Trivedi, MD
Status: Closed
The purpose of this research study is to assess the feasibility of performing hereditary breast and ovarian cancer genetic testing in the oncology clinic and to examine the knowledge and attitudes of hereditary breast and ovarian cancer genetic testing among breast and ovarian cancer patients before and after receiving the results of genetic testing. We…
Condition: Cancer / Lymphoma
Investigator: Larisa Geskin, MD
Status: Closed
This is a phase 3 clinical trial to determine the efficacy of topical SGX301 (synthetic hypericin) in combination with visible light therapy on cutaneous T-cell lymphoma (CTCL). Selected subjects can participate in 3 cycles each consisting of a 6 week treatment period where a chosen lesion will be treated with the study ointment (twice a week) followed by…
Condition: Cancer / Lung Cancer
Investigator: Brian Henick, MD
Status: Closed
The purpose of this study is to assess the overall safety and efficacy (how well the drug works) of study drug M7824 in the treatment of unresectable, non-small cell lung cancer. Another purpose is to determine whether use of the study drug in combination with chemoradiation (chemotherapy plus radiation therapy) followed by the study drug will result in…
Condition: Cancer / Head and Neck Cancer
Investigator: Richard Carvajal, MD
Status: Closed
The study involves research about MGA271 in combination with Keytruda. MGA271 targets cancer cells that make a lot of a protein called B7-H3. Another way to say it is that the cells "overexpress" the protein. Very few normal cells express B7-H3. MGA271 is though to work by recognizing cancer cells that overexpress B7-H3 and directing the body…
Condition: Cancer / Leukemia
Investigator: Mark Heaney, MD, PhD
Status: Closed
The purpose of this study is to find the dose of imetelstat that best treats myelofibrosis. (A doseis a measured amount of a drug taken at one time.) The effects of imetelstat on myelofibrosis as well as any side effects will be explored.
Condition: Cancer
Investigator: Meghna Trivedi, MD
Status: Closed
The purpose of this study is to try to learn how certain risk factors, such as age, gender, pre-existing conditions, the type of treatment you get for your cancer, and the amount of cancer drugs in your body affect whether you develop the nerve disorder and how bad your symptoms will be. There will be about 1,000 people taking part in this study.
Condition: Cancer / Breast Cancer
Investigator: Meghna Trivedi, MD
Status: Closed
The goal of this study is to determine if ribociclib in combination with letrozole as neoadjuvant endocrine therapy increases the proportion of women with PEPI score of 0 at surgery, compared to patients treated with letrozole alone therefore allowing more patients excellent outcomes without chemotherapy. The PEPI score measures the risk of breast cancer…
Condition: Cancer / Breast Cancer
Investigator: Kevin Kalinsky, MD, MS
Status: Closed
The purpose of this study is to find out what side effects (unwanted effects) are caused in patients with breast cancer who are given SGN-LIV1A (single therapy). This study will also look at other effects of SGN-LIV1A, including its effect on this type of cancer. This study is also being done to find out what side effects (unwanted effects) are caused in…
Condition: Cancer / Gynecologic Cancer
Investigator: Shaheer Khan, DO
Status: Closed
The purpose of this study is to test the good and bad effects of olaparib in combination with temozolomide for the treatment of advanced uterine leiomyosarcoma (LMS). Olaparib and temozolomide could shrink your cancer, but could also cause side effects, which are described in the risks section below. The study doctors hope to learn if the study drug will…
Condition: Cancer / Lymphoma
Investigator: Ahmed Sawas, MD
Status: Closed
The purpose of this study is to gather information about the effectiveness and safety of as drug called brentuximab vedotin when given in combination with another drug called bendamustine for Hodgkin Lymphoma. The study will assess the safety profile of the combination treatment and determine what proportion of patients achieve a complete remission.…
Condition: Cancer / Skin Cancer
Investigator: Sewanti Limaye, MD
Status: Closed
The purpose of this study is to examine the effects of KPT-330 on patients with an advanced form of skin cancer called Squamous Cell Cancer (SCC) of the head and neck, lung, or esophagus. The study drug KPT-330 is an investigational drug that
Condition: Cancer / Sarcoma
Investigator: Gary Schwartz, MD
Status: Closed
The main purpose of this research study is to test different doses of INCB059872 and see which doses are safe and tolerable in participants that have Ewing sarcoma. This study will research the effect that INCB059872 has on your cancer. Researchers will study the way INCB059872 come into and leave your body over time (pharmacokinetics). INCB059872 is a…
Condition: Cancer / Leukemia
Investigator: Alice Lee, MD
Status: Closed
This study is for children and teens who have been diagnosed with Acute Myeloid Leukemia (AML). AML is a cancer of the bone marrow, the spongy tissue inside the large bones of the body where blood cells are made. In AML, the bone marrow makes large numbers of immature white blood cells called blasts. These blast cells crowd out the normal cells of the bone…
Condition: Cancer / Liver Cancer
Investigator: Yvonne Saenger, MD
Status: Closed
The purpose of this study is to learn more about TPST-1120. The aims of the study are to find out if TPST-1120 can be given safely to people, to determine a safe dose of the study drug, if it is safe when given in combination with other anti-cancer drugs, what effects the drug may have, and to learn more about how the body processes the study drug. This is…
Condition: Cancer
Investigator: Richard Carvajal, MD
Status: Closed
This study is being done to find a safe dose level of REGN2810 alone and in combination with radiotherapy, cyclophosphamide, and radiotherapy plus cyclophosphamide together. Other purposes of this study are to measure the levels of REGN2810 in particpants blood and to collect any evidence of anti-tumor activity of REGN2810 when given alone or in combination…
Condition: Cancer / Solid Tumors
Investigator: Naiyer Rizvi, MD
Status: Closed
The purpose of this study is to find out what effects nivolumab or nivolumab given in combination with ipilimumab have on you and your cancer given the presence of genetic biomarkers (POLE and POLD1). This study will also look at the side effects of these two new immunotherapy drugs.
Condition: Cancer / Lung Cancer
Investigator: Brian Henick, MD
Status: Closed
This purpose of this study is to determine whether the tumor cells of lung cancer patients contain changes to the DNA sequence of two proteins found on the cells surface- ALK and EGFR. If the tumor contains changes to the DNA of one of these proteins, the patient may be invited to participate on a trial that will look at drugs which may target tumors that…
Condition: Cancer
Investigator: Emerson Lim, MD
Status: Closed
The purpose of the study is to evaluate the safety and tolerability of BAY 1251152 in patients with any type of solid tumors or non-indolent non-hodgkins lymphoma. The study will also investigate the pharmacokinetics (study of what the body does to the drug), as well as pharmacodynamics (study of what the drug does to the body), which may provide…
Condition: Cancer / Sarcoma
Investigator: Matthew Ingham, MD
Status: Closed
The purpose of this study is to evaluate the safety and effectiveness of a new combination treatment involving two drugs: selinexor and ixazomib, for the treatment of dedifferentiated liposarcoma, malignant peripheral nerve sheath tumor, alveolar soft part sarcoma and Ewing sarcoma. The primary objective of the study is to determine the maximum tolerated…
Condition: Cancer / Gastrointestinal
Investigator: Alfred Neugut, MD, PhD
Status: Closed
Studies have shown that cancer patients may be at high risk for financial problems because of the cost of treatment. These financial problems can be stressful and sometimes might cause patients to avoid or refuse treatment. This study will measure how often financial problems happen in patients with colorectal cancer, using questionnaires that collect…
Condition: Cancer / Uveal Melanoma
Investigator: Mariam El-Ashmawy, MD, PhD
Status: Closed
The purpose of this study is to find out what effects, good and/or bad, intermittent dosing of the medication Selumetinib will have on you and your uveal melanoma. Selumetinib is a medication that blocks (or turns off) MEK, a protein activated in some uveal melanoma cells. Selumetinib is a MEK inhibitor. Blocking MEK may stop your cancer from growing.
Condition: Cancer
Investigator: Richard Carvajal, MD
Status: Closed
The goal of this clinical research study is to find the highest safe dose of the drug MGCD265 thatcan be given to patients with advanced cancer. The safety of this drug, and the effect that it hason your disease and your body will also be studied.MGCD265 is a drug that works by blocking proteins that are important for cancer cells to grow.MGCD265 also…
Condition: Cancer / Liver Cancer
Investigator: Susan Bates, MD
Status: Closed
The purpose of this study is to compare any good and bad effects of using atezolizumab alone or with another drug called cobimetinib. About 82 people are expected to taking part in this study. Adding cobimetinib to atezolizumab could help to shrink your cancer, but it could also cause extra side effects. This study will allow the researchers to know whether…
Condition: Cancer / Breast Cancer
Investigator: Dawn Hershman, MD
Status: Closed
This study examines diffuse optical tomography (DOT) as a way to monitor the progress of the breast cancer therapy. Specifically, it looks at DOTs ability to detect non-responders early in treatment and then adjust the therapy to improve response and overall survival. DOT is favorable to more conventional forms of cancer monitoring, such as physical exams,…
Condition: Cancer
Investigator: Gary Schwartz, MD
Status: Closed
This study is for patients with metastatic or locally advanced soft tissue sarcoma (STS) who are not amenable to treatment with surgery or radiotherapy with curative intent. Patients will be treated with doxorubicin plus olaratumab versus doxorubicin plus placebo intravenously for 8 cycles. Patients without disease progression will be allowed to continue…
Condition: Cancer / Lung Cancer
Investigator: Naiyer Rizvi, MD
Status: Closed
The purpose of this study is to compare the effects of using crizotinib (also known as Xalkori) after completion of surgery, and in some cases, after chemotherapy and/or radiation therapy for ALK-positive non-small cell lung cancer patients versus placebo. Participants will be randomized to crizotinib or placebo. Participants will take crizotinib/placebo…
Condition: Cancer / Lung Cancer
Investigator: Naiyer Rizvi, MD
Status: Closed
This study is being done to test the safety and efficacy of immunotherapy based treatment combinations in patients with metastatic non-small cell lung cancer. Participants will be assigned to one of two groups, Cohort 1 or Cohort 2. Each cohort will be split into Stage 1 and Stage 2 phases.
Condition: Cancer / Solid Tumors
Investigator: Richard Carvajal, MD
Status: Closed
The main purpose of this study is to determine the best dose of MEDI0562 in combination with durvalumab, and MEDI0562 in combination with tremelimumab, that is safe and tolerable in subjects with advanced solid tumors.
Condition: Skin Cancer / Melanoma
Investigator: Richard Carvajal, MD
Status: Closed
The purpose of this study is to find out which participants with melanoma respond best to nivolumab and ipilimumab treatment and to identify tumor and blood based markers that may predict response to the combination. This study is asking that participants submit tumor tissue samples from their initial tumor specimen and blood samples before they receive…
Condition: Cancer / Multiple Myeloma
Investigator: Divaya Bhutani, MD
Status: Closed
The purpose of this study is to find out whether treatment with daratumumab and lenalidomide will make your Multiple Myeloma better. There are 2 treatment groups in this study. You will either receive lenalidomide alone or both lenalidomide and daratumumab along with medications to take before and after the daratumumab injection.
Condition: Cancer / Lung Cancer
Investigator: Balazs Halmos, MD
Status: Closed
The purpose of this study is to find out whether the drug, ruxolitinib, is effective, tolerable and safe in combination with two chemotherapy medicines called pemetrexed and cisplatin. The study will test if this combination has beneficial effects in people diagnosed with certain types of non-small cell lung cancer. Only participants with Stage IIIB,…
Condition: Cancer
Investigator: Naiyer Rizvi, MD
Status: Closed
This study is an exploratory biopsy sample study. Its purpose is to better understand why your metastatic cancer has progressed and stopped responding to checkpoint inhibitors. The information gained from this study may be valuable for understanding the mechanisms that cause resistance to immunotherapy. Cancers include: bladder cancer, brain and spinal…
Condition: Cancer / Breast Cancer
Investigator: Andrew Lassman, MD
Status: Closed
The purpose of this study is to gather information on the safety of TH-302 and its effect on patients with HER2+ breast cancer. This study will also look at how the drug is processed in the body. In addition, this study will collect data from blood, tumor, and imaging studies about this specific cancer such as the level of oxygen that is present. This may…
Condition: Cancer / Sarcoma
Investigator: Brian Henick, MD
Status: Closed
The purpose of this study is to establish the safety profile of the study drug HuMax-AXL-ADC in a mixed population of patients with specified solid tumors. HuMax-AXL-ADC binds to a specific antigen called Axl, which is expressed on the tumor cells in the cancer types treated in this trial. When the trial drug binds to the antigen on the tumor cell, the…
Condition: Cancer / Lung Cancer
Investigator: Catherine Shu, MD
Status: Closed
This study will investigate the safety and effectiveness of the study drug SGI-110 in combination with two immunotherapy drugs named durvalumab and tremelimumab in patients with small cell lung cancer who have progressed on other treatments. SGI-110 is a form of chemotherapy known as a "hypomethylating agent" and may help the immunotherapy work…
Condition: Cancer / Leukemia
Investigator: Ran Reshef, MD
Status: Closed
The purpose of this research study is to obtain information on the safety and effectiveness of PBCAR20A to treat certain types of cancers. PBCAR20A is a new investigational treatment for certain types of cancer of the blood, such as leukemia and lymphoma. It is made from a type of blood cells known as T cells. The T cells in PBCAR20A came from healthy…
Condition: Cancer / Leukemia
Investigator: Nicole Lamanna, MD
Status: Closed
This study is for patients with Richter's transformation (RT). The purpose of this study is to see if a new type of investigational drug called PNT2258 that may be effective in blocking the "on" signal to cancer cells, eventually causing them to die. We are trying to see if PNT2258 provides evidence of anti-tumor effect by measuring what…
Condition: Cancer / Gynecologic Cancer
Investigator: Jason Wright, MD
Status: Closed
HE4 (Human Epididymis Protein 4) is a biomarker expressed in the normal lining of the female genital tract and breast. We are doing this research study to if HE4 is an indicator of treatment response during initial therapy for Primary Epithelial Ovarian, Fallopian Tube and Primary Peritoneal Cancers. For this we will collect blood at specific intervals.…
Condition: Cancer / Lung Cancer
Investigator: Catherine Shu, MD
Status: Closed
The purpose of this study is to look at whether the combination of MEDI9447 and osimertinib or MEDI9447 and AZD4635 will improve the outcome in subjects with advanced epidermal growth factor receptor mutant (EGFRm) non-small cell lung cancer (NSCLC).
Condition: Cancer / Lymphoma
Investigator: Larisa Geskin, MD
Status: Closed
This is a research study to test the effectiveness of NM-IL-12 an experimental drug, in combination with low dose Total Skin Electron Beam Therapy (TSEBT) for treatment of Cutaneous T Cell Lymphoma. The study will enroll 10 subjects age 18 years and older.Treatment will consist of 3 weeks of TSEBT, and up to 27 weeks of NM-IL-12 treatment starting from day…
GSK3359609 Plus Tremelimumab for the Treatment of Advanced Solid Tumors (Non-small Cell Lung Cancer)
Condition: Cancer / Lung Cancer
Investigator: Brian Henick, MD
Status: Closed
This research study is being done to test the combination of two new drugs, GSK3359609 and Tremelimumab, in certain cancers. These two drugs are experimental which means they have not been fully tested yet and are not yet approved to treat any disease. There are two parts to this study. Part 1 determines the best dose for the study drugs and part 2 compares…
Condition: Cancer / Lymphoma
Investigator: Ran Reshef, MD
Status: Closed
Epstein-Barr Virus (EBV) is the virus that causes mononucleosis, also known as mono. Almost all adults have had EBV. For most people, EBV never causes a health problem. However, when their immune system is not working properly (people who have had a transplant and those who have immune disorders), EBV can cause certain diseases where cells grow abnormally…
Condition: Cancer / Lung Cancer
Investigator: Catherine Shu, MD
Status: Closed
The purpose of this master study is to test the effectiveness (how well the drug works), safety, and tolerability of an investigational drug called nivolumab (also known as BMS-936558) alone or in combination with standard of care therapies.
Condition: Cancer / Gynecologic Cancer
Investigator: Jason Wright, MD
Status: Closed
The purpose of this study is to find out what effects, good or bad, cobimetinib and niraparib, given with or without atezolizumab, have on you and your cancer. In this study, you will receive either cobimetinib plus niraparib or cobimetinib plus niraparib plus atezolizumab. In addition, if you are assigned to receive cobimetinib and niraparib and your…
Condition: Cancer / Breast Cancer
Investigator: Kevin Kalinsky, MD, MS
Status: Closed
The purpose of this trial is to determine whether the study drug, CX-839, reduces tumor size in patients with metastatic triple negative breast cancer when it is used in combination with the standard breast cancer treatment. CX-839 blocks the activity of a certain molecule that is overproduced by some cancer cells.
Condition: Cancer / Breast Cancer
Investigator: Kevin Kalinsky, MD, MS
Status: Closed
This study involves research; it is the first time that MLN0128 will be studied in patients who are also receiving antihormonal medication. The main purposes of the study are to determine: The risks and discomforts of MLN0128 when given with antihormonal medication. Whether giving MLN0128 in combination with antihormonal medication affects the growthof your…
Condition: Cancer / Leukemia
Investigator: Daniel Lee, MD
Status: Closed
You are being asked to take part in this study because you have acute myeloid leukemia (AML) that has come back after initial treatment (relapsed) with venetoclax combination therapy or because you did not get a complete response from your initial treatment (refractory) with venetoclax combination therapy. The purpose of this research study is to determine…
Condition: Cancer / Lymphoma
Investigator: Ahmed Sawas, MD
Status: Closed
The purpose of this study is to see if study drug IMO-8400 is safe and effective in the treatment of patientswith relapsed or refractory Diffuse Large B-Cell Lymphoma following conventional treatment.Examples of conventional treatment are radiotherapy, immunotherapy, chemotherapy, orradioimmunotherapy. Patients are scheduled to participate in this study…
Condition: Cancer / Lung Cancer
Investigator: Craig Blinderman, MD, MA
Status: Closed
Research has shown that early involvement of a team of clinicians that specialize in lessening (or palliating) many of these distressing physical and emotional symptoms and in helping patients and their family cope with a serious illness improves patients and their loved ones experience with their cancer. This team is called palliative care, and consists of…
Condition: Cancer / Breast Cancer
Investigator: Kevin Kalinsky, MD, MS
Status: Closed
The purpose of this study is to determine the effects of combining metformin and atorvastatin treatment in patients with newly diagnosed breast cancer during the interval between breast biopsy and surgery. Metformin is a common treatment for patients with diabetes, and atorvastatin is a common therapy for elevated cholesterol. We will examine the effects of…
Condition: Cancer / Breast Cancer
Investigator: Sheldon Feldman
Status: Closed
The main purpose of this study is to determine the safety and tolerability of Faslodex given directly into thebreast ducts of women with invasive breast cancer or Ductal Carcinoma In Situ (DCIS). This study is for women who have been diagnosed with invasive breast cancer or DCIS. DCIS is the presence of abnormal cells inside a milk duct in the breast, and…
Condition: Skin Cancer / Melanoma
Investigator: Richard Carvajal, MD
Status: Closed
The purpose of the first part (Phase I) of the study is to test the safety of navitoclax in combination with dabrafenib and trametinibat different doses to find out what effects, if any, it has on people. There will be about 18 people treated in this part of the study. The purpose of the second part of this study (Phase II) is to compare the good and bad…
Condition: Cancer / Lung Cancer
Investigator: Naiyer Rizvi, MD
Status: Closed
The purpose of this study is to determine if the study drug is safe and evaluate whether adjuvant therapy with the study drug will improve overall survival. The study drug is crizotinib (also known as XALKORI). The study will also collect tumor tissue and blood samples for future research.
Condition: Cancer / Solid Tumors
Investigator: Richard Carvajal, MD
Status: Closed
The purpose of the study is to test the safety, anti-tumor activity, and the ability of a new investigational drug called BMS-986179 (also known as anti-CD73) plus nivolumab (also known as BMS-936558) to block the protein CD73 from producing high amounts of a product known as adenosine which blocks your immune system from killing your cancer cells.…
Condition: Cancer / Bladder Cancer
Investigator: Christopher Anderson, MD
Status: Closed
This research is being done to study the effects, safety, and tolerability of the study drugs Nivolumab and Urelumab when given to people with advanced bladder cancer that has spread into the muscle tissue, also called Muscle-Invasive Urothelial Carcinoma of the Bladder (MIBC). Specifically, this research study will have participants either take Nivolumab…
Condition: Cancer / Bladder Cancer
Investigator: Joel DeCastro, MD, MPH
Status: Closed
The purpose of this study is to look at a new treatment for non-muscle-invasive bladder cancer. This new form of paclitaxel, a drug currently used by injection into a vein to treat various types of cancer, is designed to be instilled (injected) into the urinary bladder with a catheter (tube) placed into your bladder through your urethra (the opening where…
Condition: Cancer / Leukemia
Investigator: Ran Reshef, MD
Status: Closed
The main purpose of this research study is to investigate if a drug called Vedolizumab is safe and effective in preventing acute graft-versus-host disease (attack of donor cells on recipient healthy organs after transplant) of the gut in comparison to placebo (dummy drug). This will be studied in patients undergoing Allogeneic Hematopoietic Stem Cell…
Condition: Cancer / Multiple Myeloma
Investigator: Suzanne Lentzsch, MD
Status: Closed
The purpose of this research study is to explore the drug combination, lenalidomide, bortezomib, and dexamethasone alone or when combined with autologous stem cell transplantation to see what side effects it may have and how well it works for treatment of newly diagnosed multiple myeloma.
Condition: Cancer / Leukemia
Investigator: Mark Heaney, MD, PhD
Status: Closed
The purpose of this study is to provide samples for biomarker testing for the different MPD-RC treatment studies. As part of the treatment study you currently participating in, this is an additional research study in which you we will ask for you to donate blood and/or bone marrow samples, two nail clippings, and buccal (cheek) swab. In order to…
Condition: Cancer / Solid Tumors
Investigator: Gulam Manji, MD, PhD
Status: Closed
The purpose of this study is to find out which doses of the study drug are safe to give to patients with gastrointestinal (colon, liver, pancreas, stomach) solid tumors. The study drug is RO6958688. RO6958688 is an antibody that targets CEA on the tumor cells and may activate the immune system in targeting cancer cells. The study will also explore how the…
Condition: Cancer
Investigator: Changchun Deng, MD, PhD
Status: Closed
The purpose of the study is to evaluate the safety, tolerability and maximum tolerated dose of BAY 1143572 when taken with a drug to help the white blood cells in your blood (a drug called granulocyte colony-stimulating factor or G-CSF) in an intermittent or continuous once-daily dosing schedule in subjects with advanced cancers such as diffuse large B-cell…
Condition: Cancer / Breast Cancer
Investigator: Dawn Hershman, MD
Status: Closed
This randomized clinical trial studies prophylactic colony stimulating factor management in patients with breast, colorectal or non-small cell lung cancer receiving chemotherapy and with risk of developing febrile neutropenia. Patients receiving chemotherapy may develop febrile neutropenia. Febrile neutropenia is a condition that involves fever and a low…
Condition: Cancer / Leukemia
Investigator: Joseph Jurcic, MD
Status: Closed
The purpose of this study is to test the safety of the combination of the experimental drugs called atezolizumab and guadecitabine (not yet approved by the U.S. Food and Drug Administration FDA or any other regulatory authority outside the United States) to find out what effects, good or bad, the combination of atezolizumab and guadecitabine has on patients…
Condition: Cancer / Leukemia
Investigator: Daniel Lee, MD
Status: Closed
The purpose of this study is to measure the effectiveness and safety of an investigational drug called "alovicidib" in combination with cytarabine and daunorubicin in the treatment of AML. Investigational means that this drug has not been approved by the FDA. Cytarabine and daunorubicin are both standard of care treatments for patients with AML.…
Condition: Cancer / Solid Tumors
Investigator: Richard Carvajal, MD
Status: Closed
This study is for patients with the following types of cancer: Triple negative breast cancer, non-small cell lung cancer, mesothelioma, renal cell carcinoma, melanoma, head and and neck squamous cell carcinoma, colorectal cancer, sarcoma and pancreatic cancer. The purpose of this study is to evaluate the effectiveness of the study drug CB-839 in helping…
Condition: Cancer / Prostate Cancer
Investigator: Emerson Lim, MD
Status: Closed
You are being asked to join this study because you have either been diagnosed with prostate cancer and will be having surgery to remove your prostate or you will be having a prostate biopsy to look for prostate cancer. This study is looking to see if a new imaging device, diffuse optical tomography (DOT), can detect prostate cancer. We will also see if DOT…
Condition: Cancer
Investigator: Richard Carvajal, MD
Status: Closed
The purpose of this research study is to learn about the effects of the study drug PF 06821497, and to find the best dose for treating small cell lung cancer (SCLC), castration resistant prostate cancer (CRPC), and follicular lymphoma (FL). This study will help researchers learn about the safety of PF-06821497 and how it is absorbed, distributed, broken…
Condition: Cancer / Gynecologic Cancer
Investigator: Jason Wright, MD
Status: Closed
This study is for women with one of the following cancers, cancer of the ovary, fallopian tube or peritoneum and you had previous treatment with carboplatin or cisplatin. The purpose of this research study is to find a different treatment for platinum-resistant TP53-mutated high-grade serous (HGS) ovarian cancer patients. The investigational drug AZD1775 is…
Condition: Cancer / Lung Cancer
Investigator: Bryan Stanifer, MD
Status: Closed
This randomized phase III trial studies how well management of a tobacco treatment intervention works in reducing surgical complications in patients with newly diagnosed lung cancer who smoke cigarettes. Management of a tobacco treatment intervention compares varenicline (a drug that reduces the craving and withdrawal symptoms that occur with abstinence…
Condition: Cancer / Lung Cancer
Investigator: Brian Henick, MD
Status: Closed
The purpose of this study is to determine the amount (dose) of telaglenastat that is safe and tolerable when given together with the recommended treatment regimen of pembrolizumab, carboplatin, and pemetrexed and to determine if the combination of standard drugs with telaglenastat is more active against non-small cell lung cancer (NSCLC) than the standard…
Condition: Cancer / Solid Tumors
Investigator: Gary Schwartz, MD
Status: Closed
This is a Phase 2-3 study evaluating the effects of selinexor in patients with advanced unresectable dedifferentiated liposarcoma (DDLS). This study drug selinexor works by trapping tumor suppressing proteins within the nucleus of the cells and thus causing the cancer cells to die or stop growing. Selinexor has previously been tested in humans to define a…
Condition: Cancer
Investigator: Fabio Iwamoto, MD
Status: Closed
This clinical trial will investigate an experimental drug called FT-2102. FT-2102 targets tumor cells that have an abnormal gene (code that tells your body what proteins to make), called isocitrate dehydrogenase 1 (IDH1). Research subjects with either a Hepatobiliary Cancer (HBC), a Chondrosarcoma, an Intrahepatic cholangiocarcinoma (IHCC), a Glioma, or…
Study of sertraline (Zoloft) with ara-C in combination in patients with acute myeloid leukemia (AML)
Condition: Cancer / Leukemia
Investigator: Daniel Lee, MD
Status: Closed
The purpose of the study is to evaluate the safety, tolerability (the effect of the drug on your body), pharmacokinetics (the effect of your body on the drug) and maximum tolerated dose of sertraline in combination with cytosine arabinoside (ara-C, cytarabine) when given to patients with treatment-resistant myeloid leukemia. In addition, the effect of the…
Condition: Cancer / Solid Tumors
Investigator: Richard Carvajal, MD
Status: Closed
The primary purpose of this study is to determine a safe dose for the combinations of LY3022855 with durvalumab or LY3022855 with tremelimumab. This study will help answer the following research questions- What side effects may be experienced when taking LY3022885 with durvalumab ortremelimumab and how much LY302255, in combination with durvalumab or…
Condition: Cancer
Investigator: Matthen Mathew, MD
Status: Closed
This randomized phase II/III trial studies how well radiation therapy works with durvalumab or cetuximab in treating patients with stage III-IVB head and neck cancer who cannot take cisplatin. Radiation therapy uses high energy x-rays to kill tumor cells and shrink tumors. Monoclonal antibodies, such as durvalumab and cetuximab, may interfere with the…
Condition: Cancer / Leukemia
Investigator: Mark Heaney, MD, PhD
Status: Closed
The purpose of this study is to compare the safety, tolerability, and effectiveness of ruxolitinib, an investigational drug, compared to anagrelide, an FDA approved drug. Investigational means that the study drug has not been approved by the FDA for treatment of ET. Patients will be assigned to one of two groups. Group A will receive ruxolitinib and placebo…
Condition: Cancer / Lymphoma
Investigator: Ran Reshef, MD
Status: Closed
The purpose of this study is to find out if the experimental product, axicabtagene ciloleucel, in combination with either rituximab or lenalidomide is safe and effective in treating lymphoma. Kite Pharma, Inc., (Kite) is the sponsor of this study. The sponsor is funding this research study and has also designed the trial. The sponsor is testing an…
Condition: Cancer / Breast Cancer
Investigator: Kevin Kalinsky, MD, MS
Status: Closed
The purpose of this study is to compare the effects, good and/or bad, of study drug cobimetinib and paclitaxel for patients with metastatic truple-negative breast cancer (mTNBC). In this study, you will receive either a combination of cobimetinib and paclitaxel or placebo (no active medication) and paclitaxel. The study will also evaluate what side effects…
Condition: Cancer / Lymphoma
Investigator: Ran Reshef, MD
Status: Closed
The main purpose of this research study is to determine if the experimental product, KTE-C19, when administered after a 3 day course of chemotherapy, is safe and effective in treating relapsed or refractory (r/r) indolent non-Hodgkin B-cell lymphoma (iNHL). KTE-C19 is made from white blood cells that are removed from the individual. A virus (retrovirus) is…
Condition: Cancer / Breast Cancer
Investigator: Kevin Kalinsky, MD, MS
Status: Closed
The purpose of this study is to determine the effectiveness of the study drug, sacituzumab govitecan, to the treatment of physicians choice, in patients with metastatic, triple negative breast cancer.
Condition: Cancer / Multiple Myeloma
Investigator: Divaya Bhutani, MD
Status: Closed
Belantamab Mafodotin is a new therapy for patients with Multiple Myeloma. The drug works by combining chemotherapy and immunotherapy approach to treat Multiple Myeloma. The drug is a combination of an antibody against a target on plasma cells called BCMA and a chemotherapeutic agent called MMAF. The drug has shown activity in patients with late relapses of…
Condition: Cancer / Prostate Cancer
Investigator: Edward Gelmann, MD
Status: Closed
The purpose of this study is to compare the clinical benefit (i.e., does it help to improve or slow down the cancer) of adding study drug JNJ-56021927 to combined treatment of abiraterone acetate plus prednisone to treat patients with metastatic Castration-resistant Prostate Cancer (mCRPC). This study will also evaluate the possible side effects of study…
Condition: Cancer / Prostate Cancer
Investigator: Charles Drake, MD
Status: Closed
We are doing this study to test a drug called MGD009. MGD009 is like an antibody, which is a protein in your blood that helps get rid of germs in your body. MGD009 is made to attach to cancer cells and to T-cells, which are a part of your immune system. Certain T cells have the ability to kill other cells, including cancer cells. By attaching to cancer…
Condition: Cancer / Leukemia
Investigator: Todd Rosenblat, MD
Status: Closed
The goal of this research study is to find the safest highest dose of SL-401 that can be given to patients with AML or BPDCN. This study will also look at how SL-401 stops or slows leukemia or BPDCN growth and how SL-401 enters and leaves the body. This study will also look at certain proteins in the blood and bone marrow and how the amounts of them might…
Condition: Cancer / Gynecologic Cancer
Investigator: Jason Wright, MD
Status: Closed
The LIGHT study is a clinical research study for women who have been diagnosed with ovarian cancer. The purpose of the study is to evaluate the safety and effectiveness of an investigational drug in women with this type of cancer, using genetic information to evaluate tumors.
Study for subjects with untreated Melanoma using trial drugs Talimogene Laherparepvec and Ipilimumab
Condition: Cancer / Skin Cancer
Investigator: Bret Taback, MD
Status: Closed
The purpose of this study is to find out more about talimogene laherparepvec (formerly known as OncoVEXGM-CSF), in people with advanced melanoma when given in combination with another drug called ipilimumab. Melanoma is a type of skin cancer. Advanced melanoma means the tumor is not removable by surgery or has spread to other parts of the body. Phase 1 of…
Condition: Cancer
Investigator: Emerson Lim, MD
Status: Closed
This is the first study in humans for an investigational drug called CX-2009. CX-2009 is a Probody therapeutic containing a masked antibody (an antibody is a protein naturally occurring in the human body to fight infections and in some cases tumors) attached to a maytansine derivative (a cancer killing therapy). The study is being done to look at the…
Condition: Skin Cancer / Melanoma
Investigator: Richard Carvajal, MD
Status: Closed
The purpose of this study is to gather information on the safety of TH-302 and its effect on your cancer. This study will also look at how the drug is processed in the body. In addition, this study will collect data from blood, tumor, and imaging studies about your specific cancer such as the level of oxygen that is present. This may help us understand…
Condition: Cancer
Investigator: Mark Heaney, MD, PhD
Status: Closed
This research study will test an investigational study drug called DCC-2618. This research study will explore the following: find the highest safe dose of DCC-2618, see how often DCC-2618 should be given, see how well research participants with cancer tolerate DCC-2618, and evaluate if DCC-2618 is effective against cancer. Cancers include: brain tumors,…
Condition: Cancer / Lymphoma
Investigator: Larisa Geskin, MD
Status: Closed
You are being asked to participate in a research study because you have Cutaneous T-Cell Lymphoma/Mycosis Fungoides, and one of your symptoms is itching. This study is being done to assess the efficacy and safety of Naloxone HCL Lotion 0.5% compared to Vehicle Lotion for the treatment of itching in patients with mycosis fungoides (MF) which is a type of…
This website uses cookies as well as similar tools and technologies to understand visitors’ experiences. By continuing to use this website,
you consent to Columbia University’s usage of cookies and similar technologies, in accordance with the
Columbia University Website Cookie Notice.
I AGREE